Spinifex Pharmaceuticals Pty Limited
Spinifex Pharmaceuticals Pty Limited, headquartered in Australia, is a pioneering biopharmaceutical company focused on developing innovative pain management solutions. Founded in 2005, Spinifex has made significant strides in the industry, particularly with its flagship product, Epsolay, which addresses neuropathic pain through a unique formulation.
With a strong presence in both the Australian and international markets, Spinifex Pharmaceuticals is dedicated to advancing therapeutic options for patients suffering from chronic pain conditions. The company has garnered recognition for its commitment to research and development, positioning itself as a leader in the biopharmaceutical sector. Spinifex's dedication to improving patient outcomes through cutting-edge science sets it apart in a competitive landscape.
+71 vs industry average
Spinifex Pharmaceuticals Pty Limited’s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Spinifex Pharmaceuticals Pty Limited?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Research Services has typical carbon intensity
Industry performance
The Research Services industry has increased its overall emissions by 17% since 2019
Reported emissions
No reported emissions data is available for Spinifex Pharmaceuticals Pty Limited yet.
Spinifex Pharmaceuticals Pty Limited's reported carbon emissions
Spinifex Pharmaceuticals Pty Limited, headquartered in Australia, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Novartis AG, and as such, it inherits climate commitments and emissions data from its parent organisation.
Spinifex Pharmaceuticals is aligned with Novartis AG's sustainability initiatives, which include various climate pledges and targets. However, specific reduction targets or achievements for Spinifex Pharmaceuticals are not detailed. The climate commitments and initiatives, such as those from the Science Based Targets initiative (SBTi), CDP, and RE100, are cascaded from Novartis AG, reflecting a commitment to reducing carbon emissions across its operations.
As a subsidiary, Spinifex Pharmaceuticals is expected to contribute to the overarching goals set by Novartis AG, which focuses on reducing emissions in line with industry standards. However, without specific emissions data or reduction targets, the precise impact of Spinifex Pharmaceuticals on carbon emissions remains unclear.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Spinifex Pharmaceuticals Pty Limited’s Climate Goals (2030 & 2050)
No climate goals have been disclosed for Spinifex Pharmaceuticals Pty Limited yet.
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Climate initiatives

Science Based Targets Initiative
Inherited from Novartis AG
Carbon Disclosure Project
Inherited from Novartis AGThe Climate Pledge
Inherited from Novartis AGUN Global Compact Climate Champions initiative
Inherited from Novartis International AGRE 100
Inherited from Novartis AGClimate Action 100
Emissions comparison with industry peers
View similar organisationsNo peer comparison is available for Spinifex Pharmaceuticals Pty Limited yet.
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project